^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | Hormone Receptor Positive Breast Cancer |
| Drug: | Zonalta (Z-endoxifen hydrochloride) (Estrogen receptor antagonist, Selective estrogen receptor modulator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors
Published date:
02/16/2021
Excerpt:
Z-endoxifen in patients with gynecologic tumors, desmoid tumors, hormone receptor-positive (HR+) breast cancer, or other HR+ solid tumors at oral doses up to 360 mg daily....Patient 33 (DL8), who took letrozole for 8 years and exemestane prior to trial enrollment, experienced a partial response; patients 3, 10, and 21 (DL1, DL3, and DL6, respectively) experienced stable disease for ≥ 6 cycles.
DOI:
10.18632/oncotarget.27887
Trial ID:
